Volume 1 Supplement 1

Abstracts of the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Open Access

Anti-tumor antibody profile analysis to harness the potentials of B cells in melanomas and the natural humoral immune response

  • Beatrix Kotlan1,
  • Gabriella Liszkay2, 8, 9,
  • Miri Blank3,
  • Judit Olasz4,
  • Orsolya Csuka4, 8,
  • Timea Balatoni2,
  • Kinga Borbola2,
  • Laszlo Toth5,
  • Gyorgy Naszados6,
  • Francesco M Marincola7,
  • Maria Godeny6, 8, 9,
  • Miklos Kasler8, 9 and
  • Yehuda Shoenfeld3
Journal for ImmunoTherapy of Cancer20131(Suppl 1):O4

DOI: 10.1186/2051-1426-1-S1-O4

Published: 7 November 2013

Objectives

Natural humoral immune response and autoimmune mechanisms have great importance in keeping the balance of tumorimmunity, although it has not yet been fully understood. We aimed to reveal potential anti-tumor immune response by immunoglobulin (Ig) profile analysis of patients with metastatic melanomas.

Methods

A complex panel assay has been performed at expressed DNA and protein levels on antibodies originating from patients' peripheral blood (n = 92) or cancerous tissue biopsies (n= 87) (ETT TUKEB 16462- 02/2010). Heavy and light chain immunoglobulin variable gene regions were sequenced and analysed with Vector NTI Advance 11, Bioedit 7.0, ClustalX2.0.11, TreeView 1.6.6 programs using available databases (IMGT, Blast). Patients' sera, purified human Ig preparations and antibody fragments from tumor infiltrating B cells were tested by ELISA, immunofluorescence FACS and confocal laser microscopy.

Results

Cluster analysis revealed specific antibody variable region gene subgroups in the VH3 family, amongst which there are the ones with cancer associated antigen binding capacity. The purified immunoglobulin's strong SK-Mel28 melanoma binding potential paralleled with the clinical outcome. Some selected expressed antibody fragments showed tumor associated antigen labelling on melanoma tissues (Fig. 1). A competitive cell membrane ELISA has been standardized for measuring patients' sera in terms of various cancer associated antigen binding capacity. Data are under evaluation concerning their value to predict anti cancer humoral immune response.
Figure 1

Human purified immunoglobulin of patient (a/) and antibody fragments developed (b/) show cancer associated antigen specific binding on SK-Mel 28 cells and melanoma tissues.

Conclusions

We could prove the extensive presence of highly tumor associated unique GD3 sialilated glycosphingolipid specific antibody variable regions in patients with melanoma. Our novel panel assay confirmed the potentials of antibody profile analysis in characterizing anti tumor humoral immune response and its worth for diagnostics.

Declarations

Acknowledgement

The Harrry J. Lloyd Charitable Trust Melanoma Research Foundation Award and previous Fulbright No1206103 and OTKA T048933 Grants are acknowledged.

Authors’ Affiliations

(1)
Molecular Immunology and Toxicology, National Institute of Oncology
(2)
Oncodermatology, National Institute of Oncology
(3)
Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center
(4)
Pathogenetics, National Institute of Oncology
(5)
Oncosurgery, National Institute of Oncology
(6)
Radiological Diagnostics, National Institute of Oncology
(7)
SIDRA Medical and Research Center
(8)
Board of Directors, National Institute of Oncology
(9)
Univ Med Pharm

Copyright

© Kotlan et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement